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Risk Factors for GI Adverse Events in a Phase III
Randomized Trial of Bevacizumab in First-Line Therapy of
Advanced Ovarian Cancer: A Gynecologic Oncology
Group Study
Robert A. Burger, Mark F. Brady, Michael A. Bookman, Bradley J. Monk, Joan L. Walker,
Howard D. Homesley, Jeffrey Fowler, Benjamin E. Greer, Matthew Boente, Gini F. Fleming, Peter C. Lim,
Stephen C. Rubin, Noriyuki Katsumata, and Sharon X. Liang
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Purpose
To evaluate risk factors for GI adverse events (AEs) within a phase III trial of bevacizumab in
first-line ovarian cancer therapy.
Patients and Methods
Women with previously untreated advanced disease after surgery were randomly allocated to six
cycles of platinum-taxane chemotherapy plus placebo cycles (C)2 to C22 (R1); chemotherapy plus
bevacizumab C2 to C6 plus placebo C7 to C22 (R2); or chemotherapy plus bevacizumab C2 to C22
(R3). Patients were evaluated for history or on-study development of potential risk factors for GI
AEs defined as grade ⱖ 2 perforation, fistula, necrosis, or hemorrhage.
Results
Of 1,873 patients enrolled, 1,759 (94%) were evaluable, and 2.8% (50 of 1,759) experienced a GI
AE: 10 of 587 (1.7%, R1), 20 of 587 (3.4%, R2), and 20 of 585 (3.4%, R3). Univariable analyses
indicated that previous treatment of inflammatory bowel disease (IBD; P ⫽ .005) and small bowel
resection (SBR; P ⫽ .032) or large bowel resection (LBR; P ⫽ .012) at primary surgery were
significantly associated with a GI AE. The multivariable estimated relative odds of a GI AE were
13.4 (95% CI, 3.44 to 52.3; P ⬍ .001) for IBD; 2.05 (95% CI, 1.09 to 3.88; P ⫽ .026) for LBR; 1.95
(95% CI, 0.894 to 4.25; P ⫽ .093) for SBR; and 2.15 for bevacizumab exposure (aggregated 95%
CI, 1.05 to 4.40; P ⫽ .036).
Conclusion
History of treatment for IBD, and bowel resection at primary surgery, increase the odds of GI AEs
in patients receiving first-line platinum-taxane chemotherapy for advanced ovarian cancer. After
accounting for these risk factors, concurrent bevacizumab doubles the odds of a GI AE, but is not
appreciably increased by continuation beyond chemotherapy.
J Clin Oncol 32:1210-1217. © 2014 by American Society of Clinical Oncology

INTRODUCTION

Clinical trial information: NCT00262847.
Corresponding author: Robert A.
Burger, MD, University of Pennsylvania
School of Medicine, 3400 Civic Center
Blvd, Smilow CTR 8-104, Philadelphia,
PA 19104-5156; e-mail: burgerr@uphs
.upenn.edu.

O R I G I N A L

Angiogenesis is a process integral to disease progression for solid tumors including ovarian cancer
andislargelypromotedbyvascularendothelialgrowth
factor (VEGF).1-17 Bevacizumab, a VEGF neutralizing monoclonal antibody,18 has demonstrated
single agent activity in phase II ovarian cancer trials.19,20 Results of four phase III trials have been
reported, all demonstrating significant prolongation of progression-free survival when bevacizumab was combined with and continued beyond
standard chemotherapy.21-24

© 2014 by American Society of Clinical Oncology

The incorporation of bevacizumab into firstline ovarian cancer therapy has been controversial
because of lack of an overall survival benefit as yet
demonstrated for the entire study populations in the
two first-line phase III trials22,23 and to concerns
related to additional toxicity.25 GI wall disruption is
perhaps the most concerning adverse effect associated with bevacizumab and has been reported in
approximately 2.4% in general.25 In the phase III
first-line ovarian cancer trials, the aggregate rate was
2.9% for 1,960 women allocated to receive bevacizumab and 1.7% for 1,354 in the control groups.
The pathogenesis for this complication in the setting

GI Events in Bevacizumab Phase III Trial

of bevacizumab therapy remains unclear, and specific risk factors have
been suggested only through historical studies. Therefore, the Gynecologic Oncology Group (GOG) conducted a preplanned study embedded within its first-line phase III trial.
PATIENTS AND METHODS
As shown in Figure 1, GOG 021822 was a double-blind, placebo controlled
first-line phase III clinical trial in which women with advanced cancers were
randomly allocated to one of three postoperative regimens: six cycles of intravenous carboplatin-paclitaxel chemotherapy cycles (C) 2 to C22 (R1); chemotherapy plus bevacizumab (15 mg/kg) C2 to C6 (R2); and chemotherapy plus
bevacizumab C2 to C22 (R3). Participation required stage III incompletely
resectable intra-abdominal disease or stage IV disease and a GOG performance
status (PS) of 0 to 2. Because of concerns regarding the risk of GI perforation,
patients with evidence of intestinal obstruction requiring parenteral hydration
or nutrition were excluded. Safety was monitored through physical and laboratory assessment after each treatment cycle by using National Cancer Institute
Common Toxicity Criteria version 3.
The presence or absence of potential baseline risk factors for the development of GI adverse events (AEs) including surgical, vascular, hematologic,
and inflammatory conditions was collected on a medical history (MEDH)
form (online only). Other putative risk factors derived from the database at the
completion of the trial included age at enrollment; GOGPS; the combination
of stage and debulking level; time from surgery to C1 treatment; time from
surgery to C2 treatment; and on-study development of intestinal obstruction,
complicated (febrile or grade 4) neutropenia, or thromboembolic events.
GI AEs were defined as grade ⱖ 2 perforation, fistula, necrosis, or hemorrhage occurring as of C2 (when bevacizumab or placebo was initiated)
and ⱕ 30 days of last protocol treatment.

The primary analysis of the clinical trial was based on progression-free
survival and was conducted after 423 disease progression events or deaths had
been reported. The current study is based on data collected up to the time of
the primary data freeze, including only those with collected MEDH forms.
Univariable analyses to test the association of GI AEs with potential risk factors
were performed by using Fisher’s exact test for discrete variables and a logistic
model for continuous variables.26 A logistic model was used to estimate the
relative odds of a GI AE event because of bevacizumab, adjusted for other risk
factors.27 A time-dependent proportional hazards model was used to evaluate
the null hypothesis that the onset of febrile neutropenia, intestinal obstruction,
or thromboembolic events was not associated with subsequent onset of a GI
AE.28 All P values are two-sided.

RESULTS

Patient Characteristics
Baseline characteristics of the 1,873 patients enrolled onto GOG
0218 were similarly distributed across treatment groups (Table 1). The
median age was 60 years, over 80% had serous adenocarcinomas, and
the majority of cancers were grade 3. Forty percent had stage III disease
with residual intra-abdominal tumor implants ⬎ 1 cm in diameter
after primary cytoreductive surgery, and 26% had stage IV disease.
MEDH forms were collected on 1,759 (94%) of the 1,873 patients
enrolled. As shown in Table 2, the frequency of putative medical risk
factors for GI AEs was similarly distributed across the three treatment
groups. Of note, at least 30% of patients had a vascular risk factor, with
582 (33%) under current medical management for hypertension and
226 (12.8%) having smoked within the previous year. With respect to
GI conditions, 147 patients (8.3%) underwent small bowel resection

Registered onto the trial
(N = 1,873)

Ineligible
(n = 29)
Improper FIGO stage
(n = 13)
Inadequate specimen for central review
(n = 5)
Tumor of low malignant potential only
(n = 3)
Inappropriate histology
(n = 7)
Invalid primary tumor site
(n = 1)

Randomly assigned treatment assignment

R1: Carboplatin AUC 6
Paclitaxel 175 mg/m2
Placebo (starting on cycle 2)
Every 3 weeks × 6
Maintenance phase:
Placebo every 3 weeks for cycles 7–22

R2: Carboplatin AUC 6
Paclitaxel 175 mg/m2
Bevacizumab 15 mg/kg (starting on cycle 2)
Every 3 weeks × 6
Maintenance phase:
placebo every 3 weeks for cycles 7–22

R3: Carboplatin AUC 6
Paclitaxel 175 mg/m2
Bevacizumab 15 mg/kg (starting on cycle 2)
Every 3 weeks × 6
Maintenance phase:
Bevacizumab 15 mg/kg every 3 weeks for
cycles 7–22

Allocated to R1
Received no study treatment
Included in safety analysis

(n = 625)
(n = 4)
(n = 621)

Allocated to R2
Received no study treatment
Included in safety analysis

(n = 625)
(n = 1)
(n = 624)

Allocated to R3
Received no study treatment
Included in safety analysis

(n = 623)
(n = 5)
(n = 618)

Included in efficacy analysis
Disease progression or death
Died

(n = 625)
(n = 423)
(n = 156)

Included in efficacy analysis
Disease progression or death
Died

(n = 625)
(n = 418)
(n = 150)

Included in efficacy analysis
Disease progression or death
Died

(n = 623)
(n = 360)
(n = 138)

Fig 1. CONSORT diagram. AUC, area under the curve; FIGO, International Federation of Gynecology and Obstetrics staging system.
www.jco.org
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Table 1. Baseline Characteristics of the Source Population

Characteristic
Age
Median
Range
Raceⴱ
Non-Hispanic white
Asian
Non-Hispanic black
Hispanic
Other, specified
GOG PS
0
1
2
Stage surgical tumor debulking level†
III (macro) ⱕ 1 cm‡
III ⬎ 1 cm§
IV
Histology㛳
Serous
Endometrioid
Clear cell
Mucinous
Other/not specified
Tumor grade㛳
3
2
1
Not specified

R1
(n ⫽ 625)

R2
(n ⫽ 625)

R3
(n ⫽ 623)

No.

No.

No.

%

60
25-86

%

60
24-88

%

60
22-89

526
41
25
21
8

84
7
4
3
1

519
37
28
28
5

83
6
5
5
⬍1

521
39
27
25
4

84
6
4
4
⬍1

311
272
42

50
44
7

315
270
40

50
43
6

305
267
51

49
43
8

218
254
153

35
41
25

205
256
164

33
41
26

216
242
165

35
39
27

541
21
12
6
45

87
3
2
1
7

519
14
23
5
64

83
2
4
⬍1
10

524
24
20
8
47

84
4
3
1
7

445
102
36
42

71
16
6
7

465
86
28
46

74
14
4
7

460
97
18
48

74
16
3
8

NOTE. All clear cell tumors classified grade 3.
Abbreviations: GOG, Gynecologic Oncology Group; PS, performance status;
R1, chemotherapy plus placebo followed by placebo; R2, chemotherapy ⫹
bevacizumab followed by placebo; R3, chemotherapy ⫹ bevacizumab followed by bevacizumab.
ⴱ
Percentages may not total 100% because of rounding or categorization.
†International Federation of Gynecology and Obstetrics.
‡Stage III with ⱕ 1 cm maximal diameter for any residual abdominal tumor.
§Stage III with ⬎ 1 cm maximal diameter disease in any residual
abdominal tumor.
㛳Results from central GOG Pathology Committee review updated
September 2010.

Table 2. Distribution of Medical History Risk Factors by Randomized
Treatment Group
R1
(n ⫽ 587)

R2
(n ⫽ 587)

R3
Total
(n ⫽ 585) (N ⫽ 1,759)

No.

No.

No.

%

%

%

No.

%

Currently takes medication
for hypertension
191 32.5 201 34.2 190 32.5 582 33.0
Has in the past taken
medication for
hypertension
30 5.1 34 5.8 25 4.3 89 5.1
Ever had peripheral
vascular disease with
claudication
5 0.8
2 0.3
3 0.5 10 0.5
Ever had myocardial
infarct or
cerebrovascular
accident
11 1.9 16 2.7 15 2.6 42 2.3
Smoked within past year
81 13.8 77 13.1 68 11.6 226 12.8
Currently takes insulin for
diabetes
9 1.5 11 1.9 12 2.0 32 1.8
Currently takes oral
medication for
diabetes
31 5.3 42 7.2 42 7.2 115 6.5
Ever diagnosed with
autoimmune disease
16 2.7 15 2.6 15 2.6 46 2.6
Ever had a peptic ulcer
11 1.9 15 2.6 11 1.9 37 2.1
Ever had an intestinal
obstruction
radiographically
16 2.7 18 3.1 18 3.1 52 3.0
Ever diagnosed with
Crohn disease
2 0.3
1 0.2
1 0.2
4 0.2
Ever diagnosed with
ulcerative colitis
6 1.0
7 1.2
3 0.5 16 0.9
Ever had medication or
surgery for
inflammatory bowel
disease
7 1.2
3 0.5
3 0.5 13 0.7
Ever had medication,
hospitalization,
antibiotics, or dietary
modification for
diverticulitis
8 1.4 16 2.7 12 2.0 36 2.0
Ever had Clostridium
difficile colitis
11 1.9
8 1.3 11 1.9 30 1.7
Ever had small bowel
resection with
anastomosis
53 9.3 51 8.7 54 9.2 158 9.0
Had small bowel resection
at primary surgery
48 8.2 48 8.2 51 8.7 147 8.3
Ever had a large bowel
resection with
anastomosis
95 16.2 113 19.2 114 19.5 322 18.3
Had large bowel resection
at primary surgery
90 15.3 108 18.4 108 18.5 306 17.4
Uses corticosteroids for a
chronic condition
11 1.9
8 1.4 11 1.9 30 1.7
Uses NSAID chronically
38 6.5 34 5.8 38 6.5 110 6.3

(SBR), and 306 (17.4%) underwent large bowel resection (LBR) at
primary surgery for ovarian cancer. Relatively few had pre-existing
Crohn disease or ulcerative colitis.
The rates of potential risk factors developing after enrollment but
during treatment were low, including 39 patients (2.2%) with GI
obstruction, 86 (4.9%) with complicated neutropenia (either febrile
or grade 4), and 100 (5.7%) with either arterial or venous thromboembolic events.

Abbreviations: NSAID, nonsteroidal anti-inflammatory drug; R1, chemotherapy plus placebo followed by placebo; R2, chemotherapy ⫹ bevacizumab followed by placebo; R3, chemotherapy ⫹ bevacizumab followed
by bevacizumab.

Incidence and Spectrum of GI AEs
Fifty-seven patients (3.2%) experienced a GI AE overall, and in
50 patients (2.8%), the event occurred during or beyond treatment C2
(start of bevacizumab or placebo). Three patients (one patient with
grade 3 hemorrhage, one with grade 3 fistula, and one with grade 5
bowel necrosis) are excluded from this report because for these cases a
MEDH case report form was not submitted. As shown in Table 3, the
most common type of GI AE was perforation in 20 patients (40%),

followed by hemorrhage in 14 (28%) and fistula in 12 (24%). GI AEs
were reported in 10 of 587 patients (1.7%), 20 of 587 (3.4%), and 20 of
585 (3.4%) for patients assigned to R1, R2, and R3, respectively.
Although there were no grade 4 or 5 events in the R1 treatment group,
events classified as life-threatening or fatal occurred in six (1%) in the
R2 group and four (0.7%) in the R3 group. Figure 2 illustrates the
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confidence limits, 0.607 to 10.74), but this was not statistically significant (P ⫽ .201).
As shown in Table 4, a significant association with a GI AE was
observed for history of inflammatory bowel disease (IBD; P ⫽ .020) or
treatment of IBD (P ⫽ .005); SBR with anastomosis (P ⫽ .039) or SBR
at primary surgery (P ⫽ .032); and LBR with anastomosis (P ⫽ .016)
or LBR at primary surgery (P ⫽ .012). A multivariable logistic model
was used to estimate the odds of a GI AE associated with bevacizumab,
adjusted for significantly associated risk factors: IBD treatment, SBR at
primary surgery, and LBR at primary surgery. Relative to R1, the odds
of a GI AE were 2.15 (95% CI, 0.981 to 4.71) for R2 and 2.15 (95% CI,
0.981 to 4.70) for R3. Because the odds of a GI AE in each of the
bevacizumab treated groups relative to placebo were similar, these two
groups were combined into a single group to provide a more precise
estimate of the effect of bevacizumab relative to placebo. As shown in
Table 5, multivariable analysis estimated that bevacizumab independently increases the incidence of a GI AE by 2.15 (95% CI, 1.049 to
4.40; exact P ⫽ .032), which is similar to the univariable estimate, 2.19.
Previous treatment of IBD and LBR at primary surgery were also
independently associated with increased odds, whereas the impact on
increased odds for SBR was similar in magnitude to LBR but was not
statistically significant (P ⫽ .093).
Finally, a logistic model with a treatment-factor interaction term
demonstrated no clear evidence that bevacizumab increased the odds
(P ⬎ .10) of a GI AE associated with risk factors found to be significant
in univariable analyses (data not shown).

Table 3. Number of Grade 2 or Worse GI Adverse Event at or Beyond Cycle 2
by Type, Grade, and Treatment Group
R1

R2

R3

GI Adverse
Event Type

2

3

4

5

2

3

4

5

2

3

4

5

Total

Fistula
GI leak
Necrosis
Perforation
Bleeding
Total

1
0
0
0
2
3

3
0
1
2
1
7

0
0
0
0
0
0

0
0
0
0
0
0

1
0
0
1
3
5

2
0
0
5
2
9

1
0
0
2
0
3

0
0
0
3
0
3

1
0
0
0
3
4

3
1
0
5
3
12

0
2
0
0
0
2

0
0
0
2
0
2

12
3
1
20
14
50ⴱ

Abbreviations: R1, chemotherapy plus placebo followed by placebo; R2,
chemotherapy ⫹ bevacizumab followed by placebo; R3, chemotherapy ⫹
bevacizumab followed by bevacizumab.
ⴱ
Three patients who experienced a grade 2 or worse GI adverse event after
cycle 2 had no medical history form submitted and are therefore not included
in this table or the rest of this report.

timing of events as a function of treatment group and cycle. Forty-six
(92%) occurred during C2 through C6 (chemotherapy phase), with
38 (75%) reported by C4.
Association Between Risk Factors and GI AEs
Univariable analysis indicated no association of GI AEs with age
at enrollment (P ⫽ .593), baseline PS (P ⫽ .297), the combination of
stage and residual disease after debulking surgery (P ⫽ .378), time
from surgery to C1 treatment (P ⫽ .625), or time from surgery to C2
treatment (P ⫽ .997; data not shown). There was also no significant
association between a GI AE and on-study development of GI obstruction (P ⫽ .625), thromboembolic events (P ⫽ .202), or complicated neutropenia (P ⫽ .094, online only). In the time-dependent
proportional hazards model, the odds of a GI AE was greater among
the 74 patients in the study population who experienced febrile neutropenia before the onset of the GI AE, with a hazard ratio of 2.55 (95%

8

6
5

4

2

2

1

1

2

3

4

5

6 >6

Treatment Cycle

www.jco.org

8
7

6
5
4

4

2

2

R3

10

2

8

6

6

Fig 2. Number of treatment cycles before grade 2 or worse GI adverse event
(AE). There were seven GI AEs before
treatment cycle 2 that are not included in
this figure. R1, chemotherapy plus placebo followed by placebo; R2, chemotherapy ⫹ bevacizumab followed by placebo;
R3, chemotherapy ⫹ bevacizumab followed by bevacizumab.

6

4
3
2

2

2
1

1
0

0

C

R2

10

No. of Grade 2 or Worse GI AEs

No. of Grade 2 or Worse GI AEs

B

R1

10

To our knowledge, this is the first prospective study examining risk
factors for serious GI AEs in the context of treatment of solid tumors
with anti-VEGF agents.

No. of Grade 2 or Worse GI AEs

A

DISCUSSION

0

0
2

3

4

5

0
6 >6

Treatment Cycle

2

3

4

5

6 >6

Treatment Cycle
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Table 4. Univariable Analyses of Medical History Risk Factors and
Development of a GI Adverse Event
⫺ GI AE
(n ⫽ 1,709)
No.
Medication for hypertension
Never
Past
Current
Peripheral vascular disease
with claudication
Never
Ever
Myocardial infarct or
cerebrovascular
accident
Never
Ever
Smoked within past year
No
Yes
Current medication for
diabetes
No
Oral
Insulin
Diagnosis of autoimmune
disease
Never
Ever
Peptic ulcer
Never
Ever
Intestinal obstruction
radiographically
Never
Ever
Diagnosis of IBD
Never
Crohn disease
UC
Medication or surgery for
IBD
Never
Ever
Medication, hospitalization,
antibiotics, or dietary
modification for
diverticulitis
Never
Ever
Diagnosis of Clostridium
difficile colitis
Never
Ever
SBR with anastomosis
Never
Ever
SBR at primary surgery
No
Yes
LBR with anastomosis
Never
Ever

⫹ GI AE
(n ⫽ 50)

%

No.

%

⫺ GI AE
(n ⫽ 1,709)
P
.170

1,063
86
560

98
97
96

25
3
22

2.3
3.4
3.8
1.00

1,699
10

97
100

50
0.0

2.9
0.0

.114
1,670
39

97
93

47
3

2.7
7.1

1,490
219

97
97

43
7

2.8
3.1

1,566
112
31

97
97
97

46
3
1

2.9
2.6
3.1

1,665
44

97
96

48
2

2.8
4.4

1,672
37

97
100

50
0

2.9
0.0

1,659
50

97
96

48
2

2.8
3.9

1,692
4
13

97
100
81

47
0
3

2.7
0.0
18.75

1,699
10

97
77

47
3

2.7
23

1,674
35

97
97

49
1

2.8
2.8

1,681
28

97
93

48
2

2.8
6.7

1,560
149

97
94

41
9

2.6
5.7

1,571
138

97
94

41
9

2.5
6.1

1,403
306

97
95

34
16

2.4
5.0

.829

.909

.379

.624

.658

.020

.005

1.000

No.
LBR at primary surgery
No
Yes
Current corticosteroids for a
chronic condition
Yes
No
Current chronic NSAID use
Yes
No

%

⫹ GI AE
(n ⫽ 50)
No.

%

P
.012

1,419
290

98
95

34
16

2.3
5.2

1,680
29

97
97

49
1

2.8
3.3

1,600
109

97
99

49
1

3.0
0.9

.582

.367

Abbreviations: AE, adverse event; IBD, inflammatory bowel disease; LBR,
large bowel resection; NSAID, nonsteroidal anti-inflammatory drug; SBR,
small bowel resection; UC, ulcerative colitis.

In the initial report for GOG 0218, GI events were classified as
grade ⱖ 2 perforation, fistula, necrosis, or leak, and the rates of these
events during or after treatment cycle 2 were 1.2%, 2.8%, and 2.6% for
those enrolled to R1, R2, and R3, respectively.22 Although one may
consider these rates to be relatively low, they should be considered
clinically meaningful, as events are often life threatening,29,30 frequently require major surgical intervention, and may have long-term
adverse consequences. Thus, it is important that independent and
interactive risk factors for these complications are identified, allowing
for refined risk assessment, creation of guidelines for patient counseling, development of preventive strategies, and generation of hypotheses related to underlying pathogenic mechanisms.
In the current study, GI AEs also included ⱖ grade 2 GI hemorrhage, because mucosal ulceration manifested as bleeding was hypothesized to be mechanistically related to perforation on the basis of
pathology studies.31 Using our modified definition for the current
study, the rate of GI AEs was 3.4% in each bevacizumab treatment
group, approximately double that seen in the group assigned to chemotherapy alone and, not unexpectedly, remained an independent risk
factor in multivariable analysis. We examined only events after initiation of bevacizumab or placebo to accurately factor in relative odds
attributable to bevacizumab.

.209
Table 5. Results of a Logistic Model Assessing the Association Between GI
Adverse Events and Risk Factors Significantly Associated With GI Adverse
Events in Univariable Analyses
.039

Relative Odds of Grade ⱖ 2 GI
AE
Model Covariate

Estimated
Odds

95% CI

P

IBD treatment
LBR at primary surgery
SBR at primary surgery
BEV treatment

13.40
2.05
1.95
2.15

3.44 to 52.30
1.09 to 3.88
0.894 to 4.25
1.05 to 4.40

⬍ .001
.026
.093
.032

.032

.016

(continued in next column)

1214

Table 4. Univariable Analyses of Medical History Risk Factors and
Development of a GI Adverse Event (continued)
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Abbreviations: AE, adverse event; BEV, bevacizumab; IBD, inflammatory
bowel disease; LBR, large bowel resection; SBR, small bowel resection.
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The finding that bevacizumab exposure was associated with increased odds of a GI AE with an odds ratio of 2.15 in the current study
is supported by a meta-analysis by Hapani et al29 examining 12,294
patients with a variety of nongynecologic solid tumors from 17 randomized controlled trials. This demonstrated the incidence of GI
perforation to be 0.9% among patients receiving bevacizumab and the
relative odds of GI perforation compared with control patients to be
2.14 (95% CI, 1.19 to 3.85; P ⫽ 0.011). Interestingly, in the current
study, the odds ratio for the association of bevacizumab exposure with
a GI AE was identical (2.15) for both those receiving bevacizumab only
during the chemotherapy phase and those receiving bevacizumab
during and continued beyond the chemotherapy phase, suggesting
that there is no significant additional risk of bevacizumab continued
beyond primary platinum-taxane chemotherapy.
The etiology of GI AEs as defined above has been found to be
multifactorial and include traumatic, vascular, infectious/inflammatory, or toxic insults to the GI tract with impairment in healing as the
common denominator.29 This explains our selection of hypothetical
risk factors for investigation. Except for bevacizumab exposure, all risk
factors examined were similarly distributed across treatment groups
in the clinical trial. We found that the odds of a GI AE was significantly
associated with bevacizumab exposure; history of IBD or treatment of
IBD; and previous SBR/LBR with anastomosis or SBR/LBR at time of
primary surgery before enrolling onto GOG 0218.
Although the mechanisms by which bevacizumab may contribute to development of bowel perforation remain elusive, the preponderance of data suggests impairment of healing at sites of GI injury to
be the common denominator. Early preclinical studies before the
development of an anti-VEGF monoclonal antibody demonstrated
several naturally occurring and synthetic antiangiogenic agents to
impair healing after cutaneous surgical trauma32,33 and colonic anastomoses,34,35 whereas others demonstrated no clear impact on healing
of cutaneous wounds despite reduction in micro-vascular maturation
and granulation tissue.36-39 Data pooled from two positive phase III
randomized trials of bevacizumab in first-line therapy of metastatic
colorectal cancer involving 1,132 patients demonstrated surgical
wound healing complications in 1.3% of those receiving bevacizumab
versus 0.5% in control patients. Though inconclusive, bevacizumab
induced necrosis of tumor invading the bowel wall as an alternative
process is suggested by retrospective analyses of clinical,40,41 pathologic,30,42 and radiologic20 data. Indeed, the odds for GI perforation
appear to be greater for patients with tumors involving the abdominal
cavity, such as colorectal,29 renal cell,29 and ovarian,43 which suggests
that this is a possible mechanism. However, one cannot exclude the
possibility that such tumors are more likely to be associated with
confounding factors, such as tumor infiltration of the mesentery with
compromise blood supply, intestinal obstruction, and previous intestinal surgery. In addition, this would not explain the association of
such events with bevacizumab in patients with cancer who have no
evidence of intra-abdominal tumor and no other obvious risks.29,44 A
limitation of the current study is our inability to examine GI wall
involvement by tumor prospectively because no reliable methods of
diagnosis or documentation have been established. Another possibility is that bevacizumab could limit the blood flow to the splanchnic
microvasculature via thrombosis or vasoconstriction,45,46 leading to
GI ischemia, but evidence for this hypothesis is limited.
We also found that history of bowel resection was associated with
a two- to threefold increase in the odds of a GI AE. The vast majority of
www.jco.org

GI AEs in this subset of patients is presumed to be due to anastomotic
dehiscence, a well-known complication of intestinal surgery in general
and most commonly associated with colorectal anastomoses.47-49 The
risk of anastomotic leak in patients with advanced ovarian carcinoma
and related gynecologic malignancies undergoing colorectal surgery
may be a particular problem because of protein malnutrition that is
common when these surgeries are performed before induction chemotherapy.50 Results of a phase III trial reported by Vergote et al,51 in
which women with advanced ovarian cancer were randomly assigned
to undergo primary debulking surgery before six cycles of postoperative chemotherapy or to undergo neoadjuvant chemotherapy
(NACT) with interval debulking surgery after the third cycle of NACT,
demonstrated that the rate of bowel resection at interval debulking
surgery after NACT was approximately 50% lower (8.7% of 322 patients) than the rate at primary debulking surgery (15.5% of 310
patients).51 The direct impact on this difference on the development of
a GI AE as herein defined is unknown.
An important observation made in the current study is that not
only were bevacizumab exposure and previous treatment of IBD and
LBR at primary surgery independently associated with an increase in
the odds of a GI AE, but also that in a logistic model there was no
evidence that bevacizumab exacerbated the risk of a GI AE when these
risk factors were present.
The interpretation of our data has additional limitations. First,
several variables hypothetically associated with GI AEs were not specifically analyzed, including GI obstruction before treatment (an exclusion criterion for GOG 0218), protein malnutrition, specific
chemotherapeutic regimen (identical across treatment groups), or
bevacizumab dose density. Unfortunately we did not specifically examine laboratory indices of nutrition, such as pretreatment serum
albumin. However, we found no association with PS, which may
reflect nutritional state. Cytotoxic regimens including taxanes have
been implicated, with mechanisms including necrosis of invasive tumor, bowel wall cytotoxicity, or transmigration of bacteria secondary
to neutropenia.52-55 The association of bevacizumab dose density with
risk of GI AEs has been suggested in the meta-analysis by Hapani et
al29; however, these were univariable analyses unadjusted for other
factors such as type of combined chemotherapeutic agents. GOG 0218
utilized only one dose density for bevacizumab ⫺5 mg/kg per week.
The results of an open label phase III trial of bevacizumab in first-line
therapy consisting of the same chemotherapy regimen utilized in
GOG 0218 but with a bevacizumab dose density of 2.5 mg/kg per week
demonstrated a similar frequency of GI AEs.23 Thus far there is no
evidence of a relationship to bevacizumab dose density in the management of patients with ovarian cancer.
Second, type I and type II statistical error could have influenced
results and conclusions. Some positive findings could possibly be due
to unadjusted multiple hypothesis testing. IBDs are rare conditions
associated with development of GI perforation and fistula (particularly for Crohn disease).56-58 In the current study, though a history of
IBD or treatment thereof was reported in ⬍ 1% of the study population, those with a history of treatment for IBD had a 13-fold higher
odds of a GI AE compared with those without such history.
The more concerning issue relates to negative findings where no
statistically significant associations were found between biologically
plausible risk factors and GI AEs. There are several possible explanations, including the relatively low number of events and the low
frequency of some risk factors, creating imprecision in risk estimates.
© 2014 by American Society of Clinical Oncology
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Arguably, examples of this phenomenon may be on-study development of GI obstruction or complicated neutropenia, occurring in 39
(2.2%) and 86 (4.9%), respectively. Intestinal obstruction is a wellestablished risk factor for GI perforation59 and has retrospectively
been found to be a risk factor in a registry of approximately 2,000
patients with metastatic colorectal cancer treated with bevacizumab.41
Severe neutropenia is thought to permit trans-mural invasion of
pathogenic bacteria and has been implicated as a risk factor for enterocolonic perforation.60
Third, our results may not be completely applicable to other
primary treatment scenarios, such as for patients with no macroscopic
residual disease after initial surgery, receiving alternative regimens
such as dose-dense paclitaxel with carboplatin,61 treated with combined intraperitoneal-intravenous chemotherapy, or receiving induction NACT with interval surgical cytoreduction. Furthermore, the
results may be even less applicable to those receiving bevacizumab
with or without chemotherapy in the recurrent disease setting.
On the basis of our findings, we conclude that history of treatment for IBD and colon resection during initial surgery for advanced
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GLOSSARY TERMS

angiogenesis: the process involved in the generation of new
blood vessels. Although this is a normal process that naturally
occurs and is controlled by so-called on and off switches, blocking tumor angiogenesis (antiangiogenesis) disrupts the blood
supply to tumors, thereby preventing tumor growth.

bevacizumab: also called Avastin (Genentech, South San
Francisco, CA). Bevacizumab is a recombinant, humanized,
monoclonal antibody that binds and neutralizes the vascular
endothelial growth factor, thus acting as an antiangiogenic
agent.

www.jco.org

proportional hazards: semiparametric approach to survival analysis
developed by Cox in 1972. Unlike product-limit (Kaplan-Meier) survival analyses, which are restricted to categorical predictor variables and do not produce a
risk estimate, proportional hazards models can accommodate continuous and
ordinal variables as well as allow for the inclusion of multiple predictor variables
to compute adjusted risk estimates. Proportional hazards models are based on
the fundamental premise that all individuals have the same baseline hazard that
varies as a function of time [(t)], but that exposure to the independent variable
changes the hazard by a fixed value [h(x)]. What is parameterized in the model
is the value of this fixed effect per unit increase of the predictor variable whereas
the value of (t) remains uncharacterized.
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